Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease
3 februari 2017 uppdaterad av: Pfizer
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson's Disease And Motor Fluctuations
This study will be an open label, dose escalation study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeated daily quaque die (QD) doses given over 21 days (Day 3 to Day 23) to sequential cohorts of subjects with Parkinson's disease.
Each cohort will have 2 study periods.
For each cohort, subjects will enter Period 1 and if they meet criteria, approximately 12 subjects will be enrolled into Period 2 and dosed with PF 06649751.
Based on results observed in a previous study, Cohorts 1 and 2 will not be conducted.
Cohorts 3 - 6 will test doses uptitrated to 5 mg, 15 mg and 25 mg QD.
Doses may be modified based on emerging safety, tolerability and PK data, but the maximum daily dose that will be given in any cohort will have PK predictions at steady state that are anticipated to be below toxicokinetic limits.
An option for down titration to the previous dose level is available should the investigator consider that an AE is intolerable.
Following down titration, a single up titration to the next dose level may be attempted if the subject remains symptom free for at least 48 hrs.
Safety, tolerability and PK data of Cohort 3 will be reviewed prior to initiating the dosing in Cohorts 4 and 5. Available safety, tolerability and PK data up to Day 24 of at least 5 subjects from Cohorts 4 will be reviewed prior to initiating the dosing in Cohort 6.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
50
Fas
- Fas 1
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Brussels, Belgien, B-1070
- Pfizer Clinical Research Unit
-
-
-
-
California
-
Fountain Valley, California, Förenta staterna, 92708
- The Parkinson's and Movement Disorder Institute
-
Fountain Valley, California, Förenta staterna, 92708
- Orange Coast Memorial Medical Center
-
Long Beach, California, Förenta staterna, 90806
- Collaborative Neuroscience Network, LLC
-
-
Colorado
-
Englewood, Colorado, Förenta staterna, 80113
- Rocky Mountain Movement Disorders Center
-
Lakewood, Colorado, Förenta staterna, 80228
- Davita Clinical Research Center
-
-
Florida
-
Hallandale Beach, Florida, Förenta staterna, 33009
- MD Clinical
-
Orlando, Florida, Förenta staterna, 32806
- Compass Research, LLC
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30331
- Atlanta Center for Medical Research
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Förenta staterna, 02114
- Massachusetts General Hospital -- FOR DRUG SHIPMENT ONLY
-
-
Michigan
-
Farmington Hills, Michigan, Förenta staterna, 48334
- Quest Research Institute
-
-
New Jersey
-
Marlton, New Jersey, Förenta staterna, 08053
- PRA International
-
-
North Carolina
-
Raleigh, North Carolina, Förenta staterna, 27612
- Carolina Phase I Research, LLC
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73112
- Lynn Health Science Institute
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75231
- Neurology Consultants of Dallas, PA
-
Dallas, Texas, Förenta staterna, 75231
- Walnut Hill Medical Center
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
30 år till 80 år (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Clinical diagnosis of idiopathic Parkinson's Disease with at least 2 out of 3 cardinal characteristics (tremor, rigidity, bradykinesia)
- Mini-Mental State Examination (MMSE) ≥ 25
- Hoehn & Yahr Stage I-III inclusive
- Documented history of end of L-Dopa wearing OFF
- Cohort 5 only: History of dyskinesia following L-Dopa dosing and Score of at least 2 on Part IV, item 4.2 (functional impact of dyskinesia) of the MDS-UPDRS
Exclusion Criteria:
- Atypical/secondary parkinsonism
- History of surgical intervention for Parkinson's Disease
- Dementia/cognitive impairment that can interfere with study assessments
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: Icke-randomiserad
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Cohort 3
Titration of PF-06649751 up to 5 mg QD
|
Oral daily doses titrated up to 5mg QD
Oral daily doses titrated up to 15 mg QD
Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)
Oral daily doses titrated up to 25 mg QD
|
|
Experimentell: Cohort 4
Titration of PF-06649751 up to 15 mg QD
|
Oral daily doses titrated up to 5mg QD
Oral daily doses titrated up to 15 mg QD
Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)
Oral daily doses titrated up to 25 mg QD
|
|
Experimentell: Cohort 5
Titration of PF-06649751 up to 15 mg QDi n subjects with Levodopa-induced dyskinesias (LID)
|
Oral daily doses titrated up to 5mg QD
Oral daily doses titrated up to 15 mg QD
Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)
Oral daily doses titrated up to 25 mg QD
|
|
Experimentell: Cohort 6
Titration of PF-0649751 up to 25 mg QD
|
Oral daily doses titrated up to 5mg QD
Oral daily doses titrated up to 15 mg QD
Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)
Oral daily doses titrated up to 25 mg QD
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsram: Baseline (Day 1) up to Day 30
|
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent were events between first dose of study drug to the end of study (up to Day 30) that were absent before treatment or that worsened relative to pre-treatment state.
AEs included both serious and non-serious adverse events.
|
Baseline (Day 1) up to Day 30
|
|
Number of Participants With Laboratory Test Abnormalities
Tidsram: Baseline up to Day 30
|
Criteria for laboratory abnormalities: Hemoglobin (Hgb),hematocrit, red blood cell(RBC) count: less than(<)0.8*lower
limit of normal(LLN),mean corpuscular Hgb, mean corpuscular volume, mean corpuscular Hgb concentration:<0.9*LLN,
greater than (>)1.1*upper
limit of normal(ULN),platelet:<0.5*LLN,>1.75*ULN,lymphocyte,neutrophil:<0.8*LLN,
>1.2*ULN, basophil, eosinophil, monocyte:>1.2*ULN,
WBC:<0.6*LLN,
>1.5*ULN;total bilirubin>1.5*ULN,
aspartate aminotransferase,alanine aminotransferase,alkaline phosphatase:>3.0*ULN,total
protein,albumin:<0.8*LLN,>1.2*ULN;blood
urea nitrogen,creatinine:>1.3*ULN, uric acid>1.2*ULN;sodium<0.95*LLN,>1.05*ULN,potassium,chloride,calcium,bicarbonate:<0.9*LLN,>1.1*ULN;glucose<0.6*LLN,>1.5*ULN,urine
pH:<4.5, >8; urine: WBC, RBC greater than or equal to (>=)20/high performance field, bacteria: >20; urobilinogen, urine: glucose, ketone, protein, Hgb, nitrite, leukocyte esterase, bilirubin: >=1.
|
Baseline up to Day 30
|
|
Number of Participants With Vital Sign Abnormalities
Tidsram: Baseline up to Day 30
|
Criteria for vital sign abnormality included supine pulse rate of <40 beats per minute (bpm) or >120 bpm, standing pulse rate of <40 bpm or >140 bpm, supine and standing systolic blood pressure (SBP) <90 millimeter of mercury (mmHg), supine and standing diastolic blood pressure (DBP) <50 mmHg, supine and standing SBP of >=30 mmHg maximum (max.)
increase from baseline (IFB) and and decrease from baseline (DFB) in same posture, supine and Standing DBP of >=20 mmHg max.
increase and decrease from baseline in same posture.
Categories in which there was atleast 1 abnormality are reported in this outcome measure.
|
Baseline up to Day 30
|
|
Number of Participants With Electrocardiogram (ECG) Abnormalities
Tidsram: Baseline up to Day 30
|
Criteria for ECG abnormalities: maximum PR interval >=300 milliseconds (msec) and maximum increase PR interval increase from baseline (IFB): percent change (Pctchg) >=25 percent (%) for baseline value of >200 msec and Pctchg>=50% for baseline value of <=200 msec for PR interval, maximum QRS interval >=140 msec and a maximum IFB: Pctchg>=50%, maximum QTCF interval (Fridericia's Correction) of 450 msec to <480 msec, 480 msec to <500 msec or >=500 msec and a maximum change of <=30change<60 or >=60 msec from baseline.
|
Baseline up to Day 30
|
|
Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings
Tidsram: Baseline up to Day 30
|
Physical examination included examination of the head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems.
The examination assessed the participants for any potential changes in general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms.
Findings were considered to be clinically significant based on investigator's decision.
|
Baseline up to Day 30
|
|
Number of Participants With Clinically Significant Neurological Examination Abnormality
Tidsram: Baseline up to Day 30
|
The complete or full neurological examination included assessment of the cranial nerves; muscle strength, tone, cortical drift, abnormal movements; deep tendon reflexes; sensory exam, coordination, gait and station.
Higher cortical and motor function was considered part of the complete neurological exam.
Findings were considered abnormal as confirmed by a certified neurologist.
|
Baseline up to Day 30
|
|
Number of Participants With Categorical Scores on The Columbia Suicide Severity Rating Scale (C-SSRS)
Tidsram: Baseline up to Day 30
|
The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior.
C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior").
|
Baseline up to Day 30
|
|
Change From Baseline in Parkinson's Disease Diary For Participants With Motor Fluctuations at Day 13
Tidsram: Baseline, Day 13
|
According to Parkinson's disease diaries of participants "OFF" time was a time period when the medication no longer providing benefit with regard to mobility, slowness, and stiffness and participants experienced relatively poor overall function with worsening of tremor, rigidity, balance, or bradykinesia.
"ON" time was a time period when medication was providing benefit with regard to mobility, slowness, and stiffness.
"ON" time was classified as associated with or without troublesome dyskinesia (TD) that interfere with activities of daily living and with or without dyskinesia.
"OFF" time and "ON" time with TD were generally considered to be "bad time" with regard to motor function, whereas "ON" time without dyskinesia (WD) and with non- troublesome dyskinesia (NTD) were generally considered to be "good time".
|
Baseline, Day 13
|
|
Change From Baseline in Parkinson's Disease Diary For Participants With Motor Fluctuations at Day 20
Tidsram: Baseline, Day 20
|
According to Parkinson's disease diaries of participants "OFF" time was a time period when the medication no longer providing benefit with regard to mobility, slowness, and stiffness and participants experienced relatively poor overall function with worsening of tremor, rigidity, balance, or bradykinesia.
"ON" time was a time period when medication was providing benefit with regard to mobility, slowness, and stiffness.
"ON" time was classified as associated with or without troublesome dyskinesia (TD) that interfere with activities of daily living and with or without dyskinesia.
"OFF" time and "ON" time with TD were generally considered to be "bad time" with regard to motor function, whereas "ON" time without dyskinesia (WD) and with non- troublesome dyskinesia (NTD) were generally considered to be "good time".
|
Baseline, Day 20
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Maximum Observed Plasma Concentration (Cmax) of L-Dopa
Tidsram: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
|
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) of L-Dopa
Tidsram: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
|
|
Apparent Clearance (CL/F) of L-Dopa
Tidsram: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
|
Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
|
Terminal Half-Life (t1/2) of L-Dopa
Tidsram: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
Terminal half-life is the time measured for the plasma concentration of drug to decrease by one half.
It was calculated as dividing the natural logarithm to the base e (Log e)*2/k el, where k el is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
|
Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
|
Area Under the Curve From Time Zero Extrapolated to Infinite Time of L-Dopa
Tidsram: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
AUC (0 - inf)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf).
It is obtained from AUC (0 - t) plus AUC (t - inf).
|
Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
|
Area Under the Curve From Time Zero to Last Quantifiable Concentration of L-Dopa
Tidsram: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (C last).
|
Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
|
Apparent Volume of Distribution (Vz/F) of L-Dopa
Tidsram: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
|
Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
|
Maximum Observed Plasma Concentration (Cmax) of PF-06649751
Tidsram: Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
|
Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
|
|
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06649751
Tidsram: Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
|
Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
|
|
|
Apparent Clearance (CL/F) of PF-06649751
Tidsram: Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 22
|
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
|
Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 22
|
|
Area Under the Curve From Time Zero to End of Dosing Interval of PF-06649751
Tidsram: Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
|
Area under the concentration curve from time zero to end of dosing interval (AUCtau), where dosing interval was 12 hours.
|
Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
|
|
Minimum Observed Plasma Trough Concentration (Cmin) of PF-06649751
Tidsram: Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
|
Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
|
|
|
Ratio of Accumulation for Area Under the Curve From Time Zero to End of Dosing Interval of PF-06649751
Tidsram: Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
|
Rac was obtained from AUCtau after last dose divided by AUCtau after first dose, where AUC(tau) = Area under the concentration curve from time zero to end of dosing interval (AUCtau), where dosing interval was 12 hours.
|
Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Användbara länkar
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 oktober 2014
Primärt slutförande (Faktisk)
1 mars 2016
Avslutad studie (Faktisk)
1 mars 2016
Studieregistreringsdatum
Först inskickad
15 augusti 2014
Först inskickad som uppfyllde QC-kriterierna
21 augusti 2014
Första postat (Uppskatta)
25 augusti 2014
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
27 mars 2017
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
3 februari 2017
Senast verifierad
1 december 2016
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- B7601005
- 2014-003472-22 (EudraCT-nummer)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .